These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 17234711

  • 1. A long-acting, mono-PEGylated human growth hormone analog is a potent stimulator of weight gain and bone growth in hypophysectomized rats.
    Cox GN, Rosendahl MS, Chlipala EA, Smith DJ, Carlson SJ, Doherty DH.
    Endocrinology; 2007 Apr; 148(4):1590-7. PubMed ID: 17234711
    [Abstract] [Full Text] [Related]

  • 2. The effect of polyethylene glycol recombinant human growth hormone on growth and glucose metabolism in hypophysectomized rats.
    Zhang ZX, Liu YK, Pan H, Pan L, Zhang Q, Su HM, Zhao QL, Li H, He C.
    Growth Horm IGF Res; 2012 Feb; 22(1):30-5. PubMed ID: 22257554
    [Abstract] [Full Text] [Related]

  • 3. Long-Acting Human Growth Hormone Receptor Antagonists Produced in E. coli and Conjugated with Polyethylene Glycol.
    Wang Y, Langley RJ, Tamshen K, Jamieson SM, Lu M, Maynard HD, Perry JK.
    Bioconjug Chem; 2020 Jun 17; 31(6):1651-1660. PubMed ID: 32423203
    [Abstract] [Full Text] [Related]

  • 4. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
    Rosendahl MS, Doherty DH, Smith DJ, Carlson SJ, Chlipala EA, Cox GN.
    Bioconjug Chem; 2005 Jun 17; 16(1):200-7. PubMed ID: 15656592
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a Long-Acting Site-Specific PEGylated Murine GM-CSF Analog and Analysis of Its Hematopoietic Properties in Normal and Cyclophosphamide-Treated Neutropenic Rats.
    Cox GN, Lee JI, Rosendahl MS, Chlipala EA, Doherty DH.
    Protein J; 2020 Apr 17; 39(2):160-173. PubMed ID: 32172395
    [Abstract] [Full Text] [Related]

  • 6. Effects of growth hormone and low dose estrogen on bone growth and turnover in long bones of hypophysectomized rats.
    Kidder LS, Schmidt IU, Evans GL, Turner RT.
    Calcif Tissue Int; 1997 Oct 17; 61(4):327-35. PubMed ID: 9312204
    [Abstract] [Full Text] [Related]

  • 7. Chemical and Enzymatic Site Specific PEGylation of hGH: The Stability and in vivo Activity of PEG-N-Terminal-hGH and PEG-Gln141-hGH Conjugates.
    Grigoletto A, Mero A, Zanusso I, Schiavon O, Pasut G.
    Macromol Biosci; 2016 Jan 17; 16(1):50-6. PubMed ID: 26350165
    [Abstract] [Full Text] [Related]

  • 8. Phenyl amide linker improves the pharmacokinetics and pharmacodynamics of N-terminally mono-PEGylated human growth hormone.
    Wu L, Ji S, Shen L, Hu T.
    Mol Pharm; 2014 Sep 02; 11(9):3080-9. PubMed ID: 25115329
    [Abstract] [Full Text] [Related]

  • 9. N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior.
    Wu L, Ho SV, Wang W, Gao J, Zhang G, Su Z, Hu T.
    Int J Pharm; 2013 Sep 10; 453(2):533-40. PubMed ID: 23796830
    [Abstract] [Full Text] [Related]

  • 10. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys.
    Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL, Parry TJ.
    Eur J Pharmacol; 2002 Dec 05; 456(1-3):149-58. PubMed ID: 12450581
    [Abstract] [Full Text] [Related]

  • 11. A new PEG-beta-alanine active derivative for releasable protein conjugation.
    Pasut G, Mero A, Caboi F, Scaramuzza S, Sollai L, Veronese FM.
    Bioconjug Chem; 2008 Dec 05; 19(12):2427-31. PubMed ID: 19053302
    [Abstract] [Full Text] [Related]

  • 12. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
    Bell SJ, Fam CM, Chlipala EA, Carlson SJ, Lee JI, Rosendahl MS, Doherty DH, Cox GN.
    Bioconjug Chem; 2008 Jan 05; 19(1):299-305. PubMed ID: 18020402
    [Abstract] [Full Text] [Related]

  • 13. Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH.
    Fares F, Guy R, Bar-Ilan A, Felikman Y, Fima E.
    Endocrinology; 2010 Sep 05; 151(9):4410-7. PubMed ID: 20660071
    [Abstract] [Full Text] [Related]

  • 14. Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor.
    Doherty DH, Rosendahl MS, Smith DJ, Hughes JM, Chlipala EA, Cox GN.
    Bioconjug Chem; 2005 Sep 05; 16(5):1291-8. PubMed ID: 16173810
    [Abstract] [Full Text] [Related]

  • 15. Design of homogeneous, monopegylated erythropoietin analogs with preserved in vitro bioactivity.
    Long DL, Doherty DH, Eisenberg SP, Smith DJ, Rosendahl MS, Christensen KR, Edwards DP, Chlipala EA, Cox GN.
    Exp Hematol; 2006 Jun 05; 34(6):697-704. PubMed ID: 16728273
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein.
    Kim SJ, Kwak HH, Cho SY, Sohn YB, Park SW, Huh R, Kim J, Ko AR, Jin DK.
    Mol Pharm; 2015 Oct 05; 12(10):3759-65. PubMed ID: 26370910
    [Abstract] [Full Text] [Related]

  • 17. Design, development and evaluation of PEGylated rhGH with preserving its bioactivity at highest level after modification.
    Karbasian M, Kouchakzadeh H, Anamaghi PN, Sefidbakht Y.
    Int J Pharm; 2019 Feb 25; 557():9-17. PubMed ID: 30576790
    [Abstract] [Full Text] [Related]

  • 18. Histologic evidence: growth hormone completely prevents reduction in cortical bone gain and partially prevents cancellous osteopenia in the tibia of hypophysectomized rats.
    Chen MM, Yeh JK, Aloia JF.
    Anat Rec; 1997 Oct 25; 249(2):163-72. PubMed ID: 9335461
    [Abstract] [Full Text] [Related]

  • 19. Precise and combinatorial PEGylation generates a low-immunogenic and stable form of human growth hormone.
    Wu L, Chen J, Wu Y, Zhang B, Cai X, Zhang Z, Wang Y, Si L, Xu H, Zheng Y, Zhang C, Liang C, Li J, Zhang L, Zhang Q, Zhou D.
    J Control Release; 2017 Mar 10; 249():84-93. PubMed ID: 28131652
    [Abstract] [Full Text] [Related]

  • 20. N-Terminal Modification with Pseudo-Bifunctional PEG-Hexadecane Markedly Improves the Pharmacological Profile of Human Growth Hormone.
    Wu L, Ji S, Hu T.
    Mol Pharm; 2015 May 04; 12(5):1402-11. PubMed ID: 25849255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.